Hansa Biopharma AB (publ) (HNSA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All participants will be in listen-only mode. Since you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your question, please press star then two. Please note, today's event is being recorded. I would now like to turn the conference over to Renee Aguiar-Lucander, Chief Executive Officer. Please go ahead. Thank you. Good afternoon and good morning, everyone, and welcome to the HANSA Biopharma Conference Call to review Q2 and half-year results for 2025. I'm Renee Aguirre-Lukander, CEO for HANSA Biopharma, and joining me today is Evan Ballantyne, Chief Financial Officer, Ito Kauffman, Chief Scientific and Technology Officer, and Maria Tarnson, Chief Operating Officer and President of the US. Please turn to slide two. Please allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation, and you should therefore apply appropriate caution. Please turn to slide three. So this, today we'll discuss the progress we've made in the first half of 2025 and review the quarterly performance. I'll also share my reflections and insights based on my first few months in the role. The presentation should take roughly 50, 20 minutes, 15 to 20 minutes after which there'll be an opportunity to ask questions during a Q&A session. If you can please turn to slide four for the significant achievements in the first half. In the first half of 2025, the company achieved several notable achievements. Of note, in Q2, we stabilized the business through a directed share issue and the restructuring of existing debts held by NovaQuest. T...